-
VP39 Helix Reveals Baculovirus Assembly Principles
2026-08-21
Benning et al. use electron cryomicroscopy to resolve an infectious Autographa californica multiple nucleopolyhedrovirus nucleocapsid at 3.2 Å, showing how VP39 dimers form a 14-stranded helical tube. The structure identifies a conserved VP39 fold, a zinc finger domain, an intra-dimer sling, and closely related helical states that clarify the physical basis of baculovirus nucleocapsid assembly.
-
Hesperadin: Reframing Aurora B for Translation
2026-08-20
Hesperadin is more than a mitotic perturbation tool: it provides a mechanistic entry point for connecting Aurora B activity, chromosome surveillance, and translational questions in cancer research. This article integrates Hesperadin pharmacology with evidence that Plk1 regulates p31comet-dependent mitotic checkpoint complex disassembly, offering a practical framework for designing more informative cell-cycle studies.
-
Berberine Hydrochloride in Inflammation Workflows
2026-08-20
Berberine hydrochloride supports parallel studies of AMPK-driven metabolic regulation, LDL receptor expression, cancer-cell stress, and inflammatory signaling. This practical guide connects formulation and assay design with the oxidized self-DNA–NLRP3 findings from a recent acute kidney injury study, while clearly separating established evidence from exploratory use.
-
ATRNL1 and Cell-Specific Remodeling in Atrial Fibrillation
2026-08-19
A large-scale single-nucleus RNA-sequencing study of human left atrial tissue identifies cardiomyocyte- and macrophage-specific transcriptional changes associated with atrial fibrillation, with ATRNL1 emerging as a functional regulator of cellular stress responses and cardiac electrophysiology. The work connects population-level AF genetics with cell-resolved biology and provides a framework for prioritizing disease-relevant targets while clarifying the limits of transcriptomic and stem-cell-based validation.
-
Rapamycin (Sirolimus) and Intestinal Cell Fate
2026-08-19
Rapamycin (Sirolimus) offers a mechanistically defined way to interrogate how mTOR links epithelial polarity, YAP/TAZ activity, intestinal stem cell fate, and transit-amplifying cell expansion. This thought-leadership analysis translates findings from a CDC42–YAP–EGFR–mTOR study into experimental strategy, model selection, and translational decision-making.
-
Cell lysis buffer for WB and IP: CAF workflow
2026-08-18
Build a native protein workflow for testing CAF-driven signaling, ANGPTL4–IQGAP1 binding, and chemotherapy resistance. This guide connects inhibitor-rich lysis chemistry with Western blot, immunoprecipitation, co-IP, ELISA, and orthogonal validation while highlighting matrix-specific troubleshooting.
-
NBC19: A Cell-State Lens on NLRP3 Research
2026-08-18
NBC19 is a potent NLRP3 inflammasome inhibitor for studying IL-1β release in defined cellular systems. This article connects its validated THP1 activity with cell-state-aware assay design inspired by emerging evidence on circulating giant cancer macrophages.
-
Miltefosine in Neutrophil Differentiation Research
2026-08-17
Miltefosine is a PI3K/Akt pathway tool with a newly described application in neutrophil differentiation through Ras/MEK/ERK signaling. This guide translates the finding into practical assay design, pathway validation, dose selection, and troubleshooting workflows.
-
Live-Dead Bacterial Staining Kit for Nanomaterials
2026-08-17
The Live-Dead Bacterial Staining Kit turns membrane integrity into a practical bacterial viability assay for antimicrobial nanomaterials. This guide shows how to interpret NucGreen and EthD-III signals mechanistically, control particle interference, and avoid overstating fluorescence-based viability results.
-
AZD1480 for Reliable JAK2/STAT3 Assays
2026-08-16
This scenario-based guide explains how AZD1480 (SKU A4137) can support better-controlled viability, proliferation, cytotoxicity, and pathway assays. It connects formulation, concentration design, combination studies, and STAT3 readouts with current evidence on tumor-intrinsic IL-6–JAK2–STAT3 signaling.
-
GPER1 as a Chemoprevention Target in Prostate Cancer
2026-08-15
The reference study identifies GPER1 as a stage-sensitive protective factor during the transition from high-grade prostatic intraepithelial neoplasia to prostate cancer. Using human samples, public datasets, TRAMP mice, pharmacological intervention, and mechanistic cell assays, the authors show that GPER1 activation suppresses tumor progression and epithelial-to-mesenchymal transition.
-
Cy3 Goat Anti-Rabbit IgG (H+L) Antibody
2026-08-14
Cy3 Goat Anti-Rabbit IgG (H+L) Antibody provides a fluorescent detection step for rabbit IgG primary antibodies in immunofluorescence, IHC, ICC, and selected flow cytometry workflows. It should be used as a research reagent with assay-specific titration and controls, not as a diagnostic reagent or an automatically validated live-cell stain.
-
Bradykinin Assays: From Vascular Signal to Mechanism
2026-08-14
Bradykinin assays can reveal how endothelial signaling becomes vascular permeability, smooth muscle contraction, pain, or inflammation. This guide presents a mechanism-first design strategy, using orthogonal validation lessons from a 2025 mitochondrial study to improve interpretation of Bradykinin research.
-
0.4% Trypan Blue Solution: Practical Cell Viability
2026-08-13
0.4% Trypan Blue Solution supports rapid cell viability measurement, live/dead cell discrimination, and cell counting by staining cells with compromised membranes. It is intended for research workflows such as cell culture and cytotoxicity assays, not for diagnostic, clinical, or medical use.
-
NLRP3 Astrocyte Remodeling in Morphine Tolerance
2026-08-13
Yuan et al. identify NLRP3 inflammasome activation as a contributor to morphine tolerance and connect it with a shift in spinal astrocyte markers toward the neurotoxic A1 phenotype. Their MCC950 intervention study links reduced NLRP3 signaling with delayed tolerance and partial restoration of A2-associated S100A10, providing a pharmacological framework for studying neuroinflammation in opioid adaptation.